Biocartis Group NV announced the appointment of a global Medical Advisory Board (MAB) comprised on renowned and influential KOLs in diagnostics, pharma and hospitals to advise, inform and guide Biocartis? expedited global growth in the area of diagnostic partnerships and to provide valuable expert technology insights (e.g. complementarity of Idylla? with NGS or other technologies), expert knowledge on the clinical diagnostic needs in the field of oncology (e.g. regulatory insights, advocacy groups) and expert guidance on defining future strategies for pharma needs (e.g. reimbursement, cost and validation strategies).

The new MAB will become effective as of 28 August 2023, with additional members joining within the coming weeks. The Company is excited to welcome Anthony ?Nino? Sireci, MD, M.Sc.

and Maria Arcila, MD to the Biocartis Medical Advisory Board. Anthony ?Nino? Sireci, MD, M.Sc.

is the Senior Vice President, Diagnostics Development at Loxo Oncology at Lilly. Dr. Sireci is a board certified Clinical Pathologist and a practicing molecular pathologist. Prior to joining Loxo, he was an Assistant Professor of Pathology and Cell Biology at Columbia University and a medical director in the Laboratory of Personalized Genomic Medicine at Columbia Medical Center.

He is an active member of the Association for Molecular Pathology (AMP) where he serves on the organizations? Strategy Committee and was the former vice chair for new codes and pricing on the Economic Affairs Committee. He is also a member of the Pathology Coding Caucus in the College of American Pathologists (CAP) and the Molecular Pathology Advisory Group in the American Medical Association (AMA).

Dr. Sireci received a B.A. in chemistry from New York University, an MD from the Johns Hopkins University School of Medicine and a Masters in Biostatistics from the Mailman School of Public Health at Columbia University. He completed his residency training in Clinical Pathology in the New York-Presbyterian Hospital/Columbia, where he also served as chief resident. Maria Arcila, MD received her MD degree from the University of Pittsburgh School of Medicine and completed postgraduate training in Anatomic and Clinical Pathology at Madigan Army Medical Center, followed by subspecialty fellowships at Memorial Sloan Kettering Cancer Center (MSKCC) in Molecular Genetic Pathology and Hematopathology.

She has served as Director of the Molecular Pathology Laboratory at MSKCC and is currently the Deputy Chief of the Molecular Diagnostic Service at the same institution. Dr. Arcila?s research work highlights therapeutic and prognostic molecular markers in solid tumors and hematologic malignancies and her work focuses on the expansion, validation, and implementation of clinical tests to optimize precision medicine.